Auxilium

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Andriol10 patentsJun 2, 2026 Andriol4 patentsFeb 26, 2027 Andriol5 patentsFeb 11, 2034

Regulatory

Regulatory Timeline

19931 event

FDAOct 12

Andriol — TESTODERM

Application NDA019762 (NDA)

19971 event

FDADec 18

Andriol — TESTODERM TTS

Application NDA020791 (NDA)

20021 event

FDAOct 31

Andriol — TESTIM

Application NDA021454 (NDA)

20032 events

FDASep 26

Andriol — ANDROGEL

Application NDA021015 (NDA)

FDAJun 19

Andriol — STRIANT

Application NDA021543 (NDA)

20102 events

FDADec 29

Andriol — FORTESTA

Application NDA021463 (NDA)

FDANov 23

Andriol — AXIRON

Application NDA022504 (NDA)

20112 events

FDAOct 20

Andriol — ANDRODERM

Application NDA020489 (NDA)

FDAApr 29

Andriol — ANDROGEL

Application NDA022309 (NDA)

20121 event

FDAFeb 14

Andriol — TESTOSTERONE

Application NDA202763 (NDA)

20131 event

FDAJan 31

Andriol — TESTOSTERONE

Application NDA203098 (NDA)

20142 events

FDAJun 4

Andriol — VOGELXO

Application NDA204399 (NDA)

FDAMay 28

Andriol — NATESTO

Application NDA205488 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)